Based on the findings of the retrospective study, we undertook another cohort of patients (n = 196) with oral leukoplakia (n = 50), OSMF (n = 32), and invasive cancers involving buccal cavity (to ascertain if vimentin can be useful in oral cancer inclusive of both sites oral tongue and buccal cavity. Here, VIM is linked to Oral leukoplakia.